이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ANI Pharmaceuticals 미래 성장

Future 기준 확인 3/6

ANI Pharmaceuticals은 연간 수입과 매출이 각각 31.2%와 5.4% 증가할 것으로 예상되고 EPS는 연간 30.4%만큼 증가할 것으로 예상됩니다.

주요 정보

30.5%

수익 성장률

31.5%

EPS 성장률

Pharmaceuticals 수익 성장	27.3%
매출 성장률	6.9%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	26 Jun 2024

최근 미래 성장 업데이트

Recent updates

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

수익 및 매출 성장 예측

NasdaqGM:ANIP - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	647	81	118	176	4
12/31/2025	627	48	105	146	5
12/31/2024	554	34	68	131	5
3/31/2024	517	31	95	116	N/A
12/31/2023	487	15	100	119	N/A
9/30/2023	449	10	53	70	N/A
6/30/2023	401	-8	19	41	N/A
3/31/2023	359	-28	-7	9	N/A
12/31/2022	316	-50	-48	-31	N/A
9/30/2022	283	-69	-53	-39	N/A
6/30/2022	251	-65	-52	-48	N/A
3/31/2022	226	-63	-61	-36	N/A
12/31/2021	216	-43	-20	3	N/A
9/30/2021	212	-22	-16	10	N/A
6/30/2021	213	-17	-17	14	N/A
3/31/2021	213	-15	23	34	N/A
12/31/2020	208	-23	-53	15	N/A
9/30/2020	199	-24	-42	26	N/A
6/30/2020	198	-20	-15	49	N/A
3/31/2020	203	-1	-32	33	N/A
12/31/2019	207	6	18	46	N/A
9/30/2019	216	16	41	68	N/A
6/30/2019	215	17	28	55	N/A
3/31/2019	208	14	30	58	N/A
12/31/2018	202	15	56	67	N/A
9/30/2018	192	0	-4	56	N/A
6/30/2018	189	0	3	64	N/A
3/31/2018	187	0	-1	56	N/A
12/31/2017	177	-1	N/A	39	N/A
9/30/2017	168	7	N/A	36	N/A
6/30/2017	158	5	N/A	20	N/A
3/31/2017	145	4	N/A	23	N/A
12/31/2016	129	4	N/A	27	N/A
9/30/2016	108	8	N/A	20	N/A
6/30/2016	90	10	N/A	29	N/A
3/31/2016	78	12	N/A	27	N/A
12/31/2015	76	15	N/A	17	N/A
9/30/2015	79	33	N/A	23	N/A
6/30/2015	77	35	N/A	17	N/A
3/31/2015	64	30	N/A	18	N/A
12/31/2014	56	29	N/A	22	N/A
9/30/2014	45	11	N/A	8	N/A
6/30/2014	36	5	N/A	3	N/A
3/31/2014	35	1	N/A	0	N/A
12/31/2013	30	-5	N/A	-5	N/A
9/30/2013	25	-12	N/A	-3	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ANIP 의 연간 예상 수익 증가율( 31.2% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: ANIP 의 연간 수익( 31.2% ) US 시장( 14.9% 보다 빠르게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: ANIP 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: ANIP 의 수익(연간 5.4% ) US 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: ANIP 의 수익(연간 5.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ANIP 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

ANI Pharmaceuticals 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Consensus EPS estimates increase by 27%

Price target increased by 7.5% to US$75.50

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

Recent updates

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$46.60

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

ANI Pharma launches generic Prochlorperazine maleate tablets

Key Executive notifies of intention to sell stock

Key Executive recently sold US$673k worth of stock